Short answer
BRIP1 is a DNA-repair gene included on many hereditary breast, ovarian, and broad cancer panels. A germline pathogenic or likely pathogenic BRIP1 result is usually most important for ovarian, fallopian tube, or primary peritoneal cancer risk counseling. Breast-risk interpretation is less straightforward than for BRCA1, BRCA2, PALB2, or some other breast cancer genes, so personal screening decisions should be tied to the exact result, family history, and current genetics guidance. A BRIP1 VUS is uncertain and should not be treated like a confirmed harmful variant.
How to read the result
| Report wording | Practical meaning | What to ask next |
|---|---|---|
| Pathogenic or likely pathogenic BRIP1 variant | The lab found a BRIP1 change with enough evidence to be handled as harmful for inherited-risk counseling. | Which ovarian-risk, risk-reduction, and family-testing conversations are supported for this exact result? |
| BRIP1 variant of uncertain significance | The lab found a BRIP1 change, but the cancer-risk meaning is not established. | How should care be based on personal and family history while the variant remains uncertain? |
| Negative BRIP1 result | No reportable BRIP1 variant was found in the test performed. | Was there a known family variant, and were BRCA1, BRCA2, RAD51C, RAD51D, PALB2, Lynch genes, and other relevant genes included? |
| Tumor-only BRIP1 finding | The result may reflect a cancer-tissue change rather than inherited DNA. | Is separate germline testing needed before relatives are told to test? |
| Family variant testing | Relatives may be offered targeted testing when a confirmed familial pathogenic variant is known. | Does the report name the exact familial variant relatives should be tested for? |
Cancer-risk questions to clarify
- Ovarian, fallopian tube, and primary peritoneal cancer risk is the main BRIP1 hereditary cancer discussion.
- NCI sources group BRIP1 with RAD51C and RAD51D as moderate ovarian-risk genes and note that clinical actionability continues to be refined.
- Breast cancer risk should not be assumed from the gene name alone. Ask whether breast screening is being driven by BRIP1, family history, breast density, prior cancer, or another gene.
- A BRIP1 result does not automatically explain every breast, ovarian, pancreatic, prostate, or colorectal cancer in a family.
- A negative result is most reassuring when the test was targeted to a known family variant. Without a known family variant, it may be an uninformative negative.
When family history changes the interpretation
Follow-up matters more when BRIP1 was found only in tumor tissue, when the ovarian-risk question is being mixed with a separate breast-risk question, or when family history is stronger than the report alone. Genetics counseling can help separate inherited risk from a tumor-only clue and decide whether relatives need targeted testing.
Questions to bring to counseling
- Is this a germline result from blood, saliva, cheek cells, or another normal sample, or was BRIP1 found only in tumor testing?
- What is the exact BRIP1 variant notation and classification?
- Is the result pathogenic, likely pathogenic, VUS, likely benign, or benign?
- Which ovarian-risk or risk-reduction conversations are supported for my age and family history?
- Does this result change breast screening, or is breast screening mostly based on family history and other risk factors?
- Do relatives need targeted testing for a known family variant?
- How will I be notified if a BRIP1 VUS is reclassified?
Related guides: RAD51C and RAD51D genetic testing result interpretation, BARD1 genetic testing result interpretation, PALB2 genetic testing result interpretation, BRCA VUS result interpretation, and tumor genomic vs inherited genetic testing.
When follow-up matters more
Follow-up matters more when BRIP1 was found only in tumor tissue, when a family variant is already known, or when the ovarian-risk question is being mixed together with a separate breast-risk question. In those settings, genetics review can clarify whether the result is inherited risk, a tumor clue, or an uninformative negative that needs more context.
FAQ
What does a pathogenic BRIP1 result usually mean?
A pathogenic or likely pathogenic BRIP1 result is usually most important for ovarian, fallopian tube, or primary peritoneal cancer risk counseling.
Does BRIP1 automatically explain breast cancer risk?
No. Breast-risk interpretation is less straightforward than for BRCA1 or BRCA2, so family history and current guidance matter.
Is a BRIP1 VUS actionable?
No. A BRIP1 variant of uncertain significance should not be treated like a confirmed harmful variant.
Does a negative BRIP1 result rule out inherited risk?
Not necessarily. A negative result is most reassuring when it was targeted to a known family variant; otherwise it can be uninformative.
Does a tumor-only BRIP1 finding prove inheritance?
No. A tumor-only BRIP1 finding may reflect cancer tissue rather than inherited DNA and may need germline confirmation.
Who should get targeted family testing?
Relatives are usually offered targeted testing when a confirmed familial pathogenic variant is known and the family is being counseled around inherited risk.
How can paired tumor-normal testing help with BRIP1?
It can show whether the BRIP1 change is only in tumor tissue or also present in normal DNA, which determines whether family-risk counseling should treat it as inherited.